518990-24-4

Basic information

• Product Name: 3-Ethoxyoxalyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 3-Ethoxyoxalyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester;3-Piperidineacetic acid, 1-[(1,1-diMethylethoxy)carbonyl]-a,4-dioxo-, ethyl ester;Ethyl 2-Oxo-2-(1-Boc-4-oxo-3-piperidyl)acetate;(1-Boc-4-oxo-piperidin-3-yl)-oxo-acetic acid ethyl ester
• CAS NO: 518990-24-4
• Molecular Formula: C14H21NO6
• Molecular Weight: 297
• Mol File: 518990-24-4.mol

Chemical Properties

• Boiling Point: 420.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.202
• Storage Temp.: 2-8°C
• PKA: 7.25±0.20(Predicted)
• CAS DataBase Reference: 3-Ethoxyoxalyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Ethoxyoxalyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester(518990-24-4)
• EPA Substance Registry System: 3-Ethoxyoxalyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester(518990-24-4)

Safety Data

• Hazardous Substances Data: 518990-24-4(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 207691-65-4 N-tert-butoxycarbonyl-4-(tetrahydropyrrole-1-yl)-1,2,3,6-tetrahydropyridine 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 1142210-81-8 5-(tert-butyl) 3-ethyl 1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate 
• 518990-56-2 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid 

Relevant articles and documents

Preparation method of 1, 4, 6, 7-tetrahydro-5H-pyrazolo [4, 3-c] pyridine derivative

The invention relates to a preparation method of a 1, 4, 6, 7-tetrahydro-5H-pyrazolo [4, 3-c] pyridine derivative, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: constructing a pyrazole ring

NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Synthesis and evaluation of tetrahydropyrazolopyridine inhibitors of anion exchange protein SLC26A4 (pendrin)

Pendrin is a transmembrane chloride/anion antiporter that is strongly upregulated in the airways in rhinoviral infection, asthma, cystic fibrosis and chronic rhinosinusitis. Based on its role in the regulation of airway surface liquid depth, pendrin inhibitors have potential indications for treatment of inflammatory airways diseases. Here, a completely regioselective route to tetrahydro-pyrazolopyridine pendrin inhibitors based on 1,3-diketone and substituted hydrazine condensation was been developed. Structure-activity relationships at the tetrahydropyridyl nitrogen were investigated using a focused library, establishing the privileged nature of N-phenyl ureas and improving inhibitor potency by greater than 2-fold.

DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS

Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

OXADIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS

Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.

CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II

The invention discloses compounds of formula (I) wherein: R is a carboxylic acid or a derivative thereof; R1 and R2 are independently H or alkyl, or together R1 and R2 form an alkylene group; L1 is a